News Summary
PositiveHumana delivered strong Q3 results with raised FY2026 guidance (to $9.50+ EPS from $9.00+) and achieved a major regulatory win on Medicare Advantage Star Ratings that drove a 17% stock surge and multiple analyst upgrades. However, concurrent workforce reductions, a GAAP net income decline YoY, and adjusted EPS turning negative in Q3 signal underlying operational pressures despite near-term rating improvements.
Red flags
- •Q3 2026 GAAP net income declined 17% YoY ($162M vs. $195M) despite 26% revenue growth
- •Q3 2026 Adjusted EPS turned negative at -$0.70 per share
- •Workforce reductions announced in late October with undisclosed scope and timeline
- •Profitability recovery (3% pre-tax margin) deferred to 2028, suggesting 2027 MA bid strategy carries execution risk
Funds Buying (4)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Glenview Capital | Larry Robbins | 545K | +291K | $208M | 3.7% | +115% | Existing |
| Point72 | Steve Cohen | 207K | +109K | $79M | 0.1% | +110% | Existing |
| Duquesne Family Office | Stanley Druckenmiller | 65K | +65K | $25M | 0.6% | — | NEW |
| Soros Fund Management | Soros Family Office | 41K | +8K | $16M | 0.3% | +23% | Existing |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where HUM ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #10 of this fund's book
- 7AGILENT TECHNOLOGIES INC$257M
- 8ADVANCED MICRO DEVICES INC$239M
- 9DANAHER CORP DEL$234M
- 10HUMANA INC$208M
- 11ONTO INNOVATION INC$180M
- 12CENTENE CORP DEL$147M
- 13UBER TECHNOLOGIES INC$143M
position #33 of this fund's book
- 30Roku Inc$28M
- 31Ttm Technologies Inc$27M
- 32Rhythm Pharmaceuticals Inc$26M
- 33Humana Inc$25M
- 34Adma Biologics Inc$22M
- 35Riot Platforms Inc$18M
- 36Belite Bio Inc Sponsored$18M
Values are quarter-end position sizes. Shown only for funds where HUM ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Signal History
| Quarter | Direction | Funds | Score | vs SPY |
|---|---|---|---|---|
| Q3 2026 | LONG | 4 | 4.20 | +5.9% |
| Q1 2026 | LONG | 3 | 3.25 | +105.2% |
Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.
Insider Activity
Congressional Trading
No trades dated since Jul 1, 2026.
Earlier trades (1) — dated outside this quarter's window, not counted in the badges
| Member | Chamber | State | Type | Amount Range | Transaction Date | Filed | Src |
|---|---|---|---|---|---|---|---|
| Alan Armstrong | senate | — | BUY | $1,001 - $15,000 | 2026-03-27 | 2026-07-21 | ↗ |
Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures. Members often file weeks or months after trading, so trades are placed by transaction date: the badges above count trades dated since Jul 1, 2026.